Kardigan prepared to bring three late-stage cardiac assets to the public markets with a planned $320 million Nasdaq IPO, funded in part by a cardiovascular leadership team with ties to prior MyoKardia success. The proceeds are earmarked for development of danicamtiv for genetic dilated cardiomyopathy and ataciguat for calcific aortic valve stenosis, along with tonlamarsen for liver-directed blood-pressure control after hospitalization for hypertension. Separately, a distinct cardiac pipeline update came through clinical progress elsewhere: in a separate IPO-bound market move, Kardigan’s filing frames a multi-asset cash plan designed to extend into phase 3 while maintaining near-term trial execution momentum.